JANX
$16.12
+$0.12 (0.75%)+0.75%
ClosedLoading chart...
IndexN/A
Market Cap0.98B
Enterprise Value0.82B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-9.83
P/S85.51
P/B0.89
P/C-10.27
EV/EBITDA-7.39
EV/SalesN/A
EPS (ttm)-1.64
EarningsN/A
Gross Margin79.71%
Oper. Margin-1576.67%
Profit Margin-1136.25%
Volume0.43M
Shs Outstand0.06B
Change0.75%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $10.59M | $8.08M | $8.61M | $3.64M | $0.00 | $0.00 |
| Cost of Revenue | $2.06M | $1.96M | $841.00K | $0.00 | $13.00K | $6.00K |
| Gross Profit | $8.53M | $6.13M | $7.77M | $3.64M | $-13.00K | $-6.00K |
| Gross Margin | 80.54% | 75.81% | 90.23% | 100.00% | N/A | N/A |
| Operating Expenses | $107.38M | $79.11M | $74.86M | $36.57M | $4.83M | $3.77M |
| Operating Income | $-98.85M | $-72.98M | $-67.09M | $-32.93M | $-4.84M | $-3.77M |
| Operating Margin | -933.58% | -902.87% | -779.04% | -905.39% | N/A | N/A |
| Net Income | $-68.99M | $-58.29M | $-63.06M | $-32.67M | $-6.78M | $-4.24M |
| Net Margin | -651.62% | -721.18% | -732.22% | -898.32% | N/A | N/A |
| EPS (Basic) | $-1.28 | $-1.32 | $-1.52 | $-0.79 | $-0.16 | $-0.10 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $1.06B | $380.41M | $364.01M | $379.82M | $16.22M | $679.00K |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $38.73M | $36.06M | $43.27M | $13.50M | $30.86M | $8.62M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.02B | $344.35M | $320.74M | $366.33M | $-14.64M | $-7.94M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.02B | $344.35M | $320.74M | $366.33M | $-14.64M | $-7.94M |
| Total Liabilities & Stockholders Equity | $1.06B | $380.41M | $364.01M | $379.82M | $16.22M | $679.00K |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-68.99M | $-58.29M | $-63.06M | $-32.67M | $-6.78M | $-4.24M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-43.81M | $-50.58M | $-42.92M | $-16.98M | $-4.37M | $-3.83M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 MillionBenzinga Why Janux Therapeutics Crushed the Market TodayThe Motley Fool The Latest Analyst Ratings For Janux TherapeuticsBenzinga Analyst Ratings For Janux TherapeuticsBenzinga Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price StrengthZacks Investment Research A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 AnalystsBenzinga Janux (JANX) Rises Almost 50% in a Week on Buyout RumorsZacks Investment Research
Show 12 more stories
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research Why Janux Therapeutics Stock Is Crushing It This WeekThe Motley Fool Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionBenzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayBenzinga Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a BetZacks Investment Research Why Janux Therapeutics Stock Soared as the Market Sagged TodayThe Motley Fool After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)Zacks Investment Research Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to TradeZacks Investment Research Forecasting The Future: 4 Analyst Projections For Janux TherapeuticsBenzinga 2 Stocks That Have More Than Tripled This Year: Are They Buys?The Motley Fool B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To KnowBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Discover more
You may be interested in